Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 121-124 , Summer 2009

Pathologic Evaluation of Malignant Pleural Mesothelioma

  • Lucian R. Chirieac, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Lucian R. Chirieac, MD, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA
    • ,
  • Joseph M. Corson, MD

References 

  1. Churg A, Cagle PT, Roggli VL, American Registry of pathology: Armed Forces Institute of Pathology (U.S.), in Tumors of the Serosal Membranes: Washington, DC: American Registry of Pathology in Collaboration with the Armed Forces Institute of Pathology, 2006
  2. Travis WD World Health Organization, International Agency for Research on Cancer, International Academy of Pathology, International Association for the Study of Lung Cancer. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Publishing; 2004;
  3. Bueno R, Reblando J, Glickman J, et al. Pleural biopsy: A reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg. 2004;78:1774–1776
  4. Foo WC, Hofer MD, Sugarbaker DJ, et al. The Accuracy of Pretreatment Biopsy of Pleural Malignant Mesothelioma in Predicting Histopathologic Type in Extrapleural Pneumonectomy. Laboratory Investigation. 2008;88(1556 Suppl):341A–342A
  5. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63
  6. Travis WD. Histological Typing of Lung and Pleural Tumours. (ed 3). 1999;Berlin; New York, Springer-Verlag
  7. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591–1603
  8. Gordon GJ, Dong L, Yeap BY, et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst. 2009;101:678–686
  9. Lester SC. Manual of Surgical Pathology. (ed 2). Edinburgh/New York: Elsevier Churchill Livingstone; 2006;
  10. Cagle PT, Wessels R, Greenberg SD. Concurrent mesothelioma and adenocarcinoma of the lung in a patient with asbestosis. Mod Pathol. 1993;6:438–441
  11. Cagle PT, Re C, Cagle PT, et al. Concurrent mesothelioma and adenocarcinoma of the lung in a patient with asbestosis. Mod Pathol. 1993;6:438;7:148-149, 1994
  12. Roggli VL, Vollmer RT. Twenty-five years of fiber analysis: What have we learned?. Hum Pathol. 2008;39:307–315
  13. Dodson RF, Hammar SP. Asbestos: Risk Assessment, Epidemiology, and Health Effects. Boca Raton, FL: Taylor & Francis; 2006;
  14. Hammar SP. Macroscopic, histologic, histochemical, immunohistochemical, and ultrastructural features of mesothelioma. Ultrastruct Pathol. 2006;30:3–17
  15. Allen TC. Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies. Arch Pathol Lab Med. 2005;129:1415–1420
  16. Addis B, Roche H. Problems in mesothelioma diagnosis. Histopathology. 2009;54:55–68
  17. Litzky LA. Pulmonary sarcomatous tumors. Arch Pathol Lab Med. 2008;132:1104–1117
  18. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008;132:397–401
  19. Suster S, Moran CA. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma. Adv Anat Pathol. 2006;13:316–329
  20. Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? (A review and update). Hum Pathol. 2007;38:1–16
  21. Granville L, Laga AC, Allen TC, et al. Review and update of uncommon primary pleural tumors: A practical approach to diagnosis. Arch Pathol Lab Med. 2005;129:1428–1443
  22. Attanoos RL, Dojcinov SD, Webb R, et al. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology. 2000;37:224–231
  23. Chirieac LR, Pinkus GS, Pinkus JL, et al. Sarcomatoid Malignant Mesothelioma: Immunohistochemical Characteristics of 24 Cases. Laboratory Investigation. 2006;86(1422 Suppl):305A
  24. Lucas DR, Pass HI, Madan SK, et al. Sarcomatoid mesothelioma and its histological mimics: A comparative immunohistochemical study. Histopathology. 2003;42:270–279
  25. Padgett DM, Cathro HP, Wick MR, et al. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surg Pathol. 2008;32:123–127

PII: S1043-0679(09)00069-0

doi: 10.1053/j.semtcvs.2009.06.005

Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 121-124 , Summer 2009

Article Tools